A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

NCT06601517 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Subject
Overweight Subject

Interventions

DRUG: Repaglinide
DRUG: Atorvastatin
DRUG: Digoxin
DRUG: Rosuvastatin
DRUG: HDM1002

Sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.